CEL SCI CORP
NYSE · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
CEL-SCI Corporation is a clinical-stage biotechnology company developing Multikine, an investigational immunotherapy intended to be given prior to standard treatment for patients with advanced head and neck cancer, along with other immune-based therapy candidates.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| KERSTEN GEERT RChief Executive Officer | Buy | $138K | 100,000at $1.38 | Aug 25, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable CVM activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.